Abbott Faces $219M FCA Trial Over Off-Label Stent Marketing
By Jess Krochtengel · March 22, 2016, 8:25 PM EDT
A former Abbott Laboratories sales director on Tuesday told a Texas federal jury the company charged Medicare $219 million for unauthorized uses of its stents, as a decade-old False Claims Act...
To view the full article, register now.